Merck Remains Active In Pursuit Of Mevacor Rx-to-OTC Switch In U.S.
This article was originally published in The Tan Sheet
Executive Summary
Merck continues to work with FDA over a possible switch of Mevacor (lovastatin) to over-the-counter status in the U.S. this year
You may also be interested in...
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March